http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111944021-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate | 2020-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111944021-B |
| titleOfInvention | CD47 affinity peptide and its application |
| abstract | The present invention relates to CD47 affinity peptides and uses thereof. The amino acid sequence of the affinity peptide is shown in SEQ ID NO. 1, or a mutant peptide in which one amino acid is mutated to alanine, or from asparagine to aspartic acid. The peptide obtained by screening and optimization of the present invention can block the interaction between CD47/Sirpɑ while having affinity for CD47, can significantly improve the phagocytosis and clearance of tumor cells by macrophages, and effectively inhibit the growth of tumors, thereby treating Tumors or other types of disease. |
| priorityDate | 2020-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 127.